About
Funding strategy built around the company — not only the solicitation.
Specific Aims Intelligence grew out of a pattern that kept repeating in client conversations. Companies would arrive ready to start writing, and the honest answer was often that they shouldn’t — not yet. The timing was wrong, a piece of evidence was missing, or a factor outside their control made that cycle a poor bet. Some had already paid someone to begin writing before finding this out. Others had the opposite problem: they were underselling what they’d built, positioning for a mechanism well below what their data could support.
Both failures start in the same place. Grant work is usually sold as writing, so it begins at the writing — while the decisions that determine whether an application is competitive happen well before a word is drafted.
This firm was founded by Snider Desir, PhD, whose background spans biomedical research, target validation in pharma, and commercial roles in life-science technology. That combination matters here: evaluating whether a scientific claim is actually supported by its evidence is the same discipline that determines whether a Specific Aims section holds up under review, and the commercialization narrative is an argument about market and adoption, not a section to fill.